Basking Biosciences Completes $5.4M Seed Financing: Funds to Support Development of the 1st Reversible Thrombolytic Therapy for Acute Ischemic Stroke

December 7, 2020

Basking Biosciences, Inc., a privately-held biopharmaceutical company developing a next-generation treatment for acute ischemic stroke* (AIS) announced an initial closing of a $5.4M Seed Series financing.

Basking Biosciences notes the investor syndicate includes Rev1 Ventures, Broadview Ventures, and Viva BioInnovator. Concurrent with the financing, Ryan Helon of Rev1, Thomas Needham of Broadview, and Dr. Dan Meyers have joined Basking’s Board of Directors.

Basking is developing the first reversible thrombolytic therapy for acute ischemic stroke (AIS). The Company’s development candidate, DTRI-031, is an RNA aptamer that inhibits von Willebrand Factor (vWF). Basking is co-developing a matched oligonucleotide reversal agent, DTRI-025, for as-needed, rapid reversal of DTRI-031. Basking’s paired therapy has the potential to significantly expand the population of patients that receives acute thrombolytic therapy by extending the treatment window to 24 hours post stroke onset and aligns well with the urgent need in medicine for precision-based therapeutics in cardiovascular disease. The program is expected to enter into human clinical trials in Q2 2021.

Basking’s technology is based on two decades of translational research on RNA aptamers as therapeutic agents for cardiovascular diseases conducted by company founders Professor Bruce Sullenger and Dr. Shahid Nimjee at Duke University and The Ohio State University Wexner Medical Center respectively.

Tom Needham of Broadview Ventures said, “At Broadview, we focus exclusively on investing in promising technologies to better treat cardiovascular and neurovascular disease. We are extremely excited about the potential for Basking’s therapy to extend the treatment window and expand the number of patients eligible to receive acute stroke intervention.”

“We are delighted that this strong group of early investors recognize the devastating global burden of stroke, and have joined us to advance Basking’s novel stroke therapy into clinical development,” said Richard Shea, Chief Executive Officer of Basking Biosciences. “We believe that vWF, the only non-redundant mediator of platelet adhesion and aggregation, is the ideal target to effect consistent thrombolysis in AIS patients.”

*Over 15 million people worldwide suffer from a stroke each year. With 6 million deaths annually, stroke is the second leading cause of death worldwide after cardiovascular disease and is the leading cause of long-term disability. In the United States, ischemic stroke affects approximately 700,000 people annually and results in 140,000 deaths.

AIS patients who require urgent revascularization are undertreated with the current standard of care. The only FDA-approved pharmacologic therapy for clot thrombolysis, recombinant tissue plasminogen activator (rTPA), has a narrow treatment window that restricts its use to 3 – 4.5 hours post stroke onset. Initiating rTPA treatment beyond the 4.5-hour window also increases the risk of intracerebral hemorrhage, leading to high morbidity and mortality in stroke patients. The narrow treatment window required for safe and effective use of rTPA significantly limits its use because many AIS patients present beyond the 3 – 4.5-hour time window, and therefore are ineligible for therapy.

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.
Vicarious Surgical added Philip Liang and Ric Fulop to their Board of Directors. 

By using this website you agree to accept Medical Device News Magazine Privacy Policy